Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:APNHY NASDAQ:BBIO NYSE:RDY NASDAQ:SUPN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPNHYAspen Pharmacare$8.14$8.13$5.24▼$8.86$3.63B0.77150 shs2 shsBBIOBridgeBio Pharma$69.12-1.7%$71.30$31.77▼$84.94$13.54B1.023.36 million shs1.83 million shsRDYDr. Reddy's Laboratories$13.60+0.3%$13.49$12.19▼$16.17$11.35B0.272.98 million shs723,634 shsSUPNSupernus Pharmaceuticals$48.21-2.4%$49.99$30.83▼$59.68$2.80B0.57778,535 shs526,839 shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPNHYAspen Pharmacare0.00%-7.66%-3.90%+1.88%+23.33%BBIOBridgeBio Pharma0.00%+4.52%-3.56%+1.44%+110.48%RDYDr. Reddy's Laboratories0.00%-0.07%+0.08%-6.07%-5.16%SUPNSupernus Pharmaceuticals0.00%-2.47%-4.33%-5.21%+47.75%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPNHYAspen Pharmacare$8.14$8.13$5.24▼$8.86$3.63B0.77150 shs2 shsBBIOBridgeBio Pharma$69.12-1.7%$71.30$31.77▼$84.94$13.54B1.023.36 million shs1.83 million shsRDYDr. Reddy's Laboratories$13.60+0.3%$13.49$12.19▼$16.17$11.35B0.272.98 million shs723,634 shsSUPNSupernus Pharmaceuticals$48.21-2.4%$49.99$30.83▼$59.68$2.80B0.57778,535 shs526,839 shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPNHYAspen Pharmacare0.00%-7.66%-3.90%+1.88%+23.33%BBIOBridgeBio Pharma0.00%+4.52%-3.56%+1.44%+110.48%RDYDr. Reddy's Laboratories0.00%-0.07%+0.08%-6.07%-5.16%SUPNSupernus Pharmaceuticals0.00%-2.47%-4.33%-5.21%+47.75%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPNHYAspen Pharmacare 0.00N/AN/AN/ABBIOBridgeBio Pharma 2.88Moderate Buy$88.9028.62% UpsideRDYDr. Reddy's Laboratories 2.00Hold$16.9024.30% UpsideSUPNSupernus Pharmaceuticals 2.43Hold$62.1728.95% UpsideCurrent Analyst Ratings BreakdownLatest APNHY, BBIO, RDY, and SUPN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/19/2026BBIOBridgeBio Pharma CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageNeutral$82.005/15/2026BBIOBridgeBio Pharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D)5/12/2026RDYDr. Reddy's Laboratories Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C+) ➝ Hold (C)5/11/2026BBIOBridgeBio Pharma HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$100.00 ➝ $110.004/29/2026BBIOBridgeBio Pharma Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$95.00 ➝ $102.004/28/2026BBIOBridgeBio Pharma MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$106.004/27/2026RDYDr. Reddy's Laboratories Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold (C) ➝ Hold (C+)4/27/2026BBIOBridgeBio Pharma HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$100.004/27/2026SUPNSupernus Pharmaceuticals Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold4/23/2026RDYDr. Reddy's Laboratories The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeNeutral ➝ Sell4/9/2026BBIOBridgeBio Pharma Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$100.00(Data available from 5/24/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPNHYAspen Pharmacare$2.39B1.52$1.07 per share7.63N/A∞BBIOBridgeBio Pharma$502.08M26.96N/AN/A($11.58) per share-5.97RDYDr. Reddy's Laboratories$3.58B3.17$0.86 per share15.77$5.15 per share2.64SUPNSupernus Pharmaceuticals$718.95M3.89$3.78 per share12.77$18.55 per share2.60Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPNHYAspen Pharmacare-$59.67MN/AN/A11.63N/AN/AN/AN/AN/ABBIOBridgeBio Pharma-$724.93M-$3.74N/A276.48N/A-124.42%N/A-65.81%8/4/2026 (Estimated)RDYDr. Reddy's Laboratories$484.20M$0.5823.4421.931.8812.90%12.16%8.12%7/22/2026 (Estimated)SUPNSupernus Pharmaceuticals-$38.55M-$0.51N/A13.351.04-3.74%13.07%9.66%8/4/2026 (Estimated)Latest APNHY, BBIO, RDY, and SUPN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2026Q4 25/26RDYDr. Reddy's Laboratories$0.09$0.06-$0.03-$0.03$886.58 million$852.55 million5/7/2026Q1 2026BBIOBridgeBio Pharma-$0.70-$0.84-$0.14-$0.84$178.07 million$194.52 million2/24/2026Q4 2025BBIOBridgeBio Pharma-$0.75-$1.00-$0.25-$1.00$150.71 million$154.18 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAPNHYAspen Pharmacare$0.070.86%N/AN/AN/ABBIOBridgeBio PharmaN/AN/AN/AN/AN/ARDYDr. Reddy's Laboratories$0.070.51%+6.96%12.07%N/ASUPNSupernus PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPNHYAspen Pharmacare0.363.642.66BBIOBridgeBio PharmaN/A1.521.48RDYDr. Reddy's Laboratories0.031.801.35SUPNSupernus PharmaceuticalsN/A1.961.72Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPNHYAspen PharmacareN/ABBIOBridgeBio Pharma99.85%RDYDr. Reddy's Laboratories3.85%SUPNSupernus PharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipAPNHYAspen PharmacareN/ABBIOBridgeBio Pharma14.23%RDYDr. Reddy's Laboratories2.00%SUPNSupernus Pharmaceuticals8.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPNHYAspen Pharmacare9,557446.25 millionN/ANot OptionableBBIOBridgeBio Pharma400195.86 million167.99 millionOptionableRDYDr. Reddy's Laboratories27,811834.65 million817.96 millionOptionableSUPNSupernus Pharmaceuticals58058.04 million52.93 millionOptionableAPNHY, BBIO, RDY, and SUPN HeadlinesRecent News About These CompaniesWall Street Zen Downgrades Supernus Pharmaceuticals (NASDAQ:SUPN) to BuyMay 23 at 1:40 AM | americanbankingnews.comSupernus Reaches Milestone, Triggers Contingent Value Rights PaymentMay 20, 2026 | tipranks.comSupernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Given Consensus Recommendation of "Hold" by BrokeragesMay 16, 2026 | americanbankingnews.com3 growth stocks we approach with cautionMay 15, 2026 | msn.com5 Revealing Analyst Questions From Supernus Pharmaceuticals’s Q1 Earnings CallMay 15, 2026 | finance.yahoo.comSupernus Pharmaceuticals, Inc. (SUPN) Presents at Bank of America Global Healthcare Conference 2026 TranscriptMay 13, 2026 | seekingalpha.comSupernus Pharmaceuticals (NASDAQ:SUPN) Upgraded to "Strong-Buy" at Wall Street ZenMay 9, 2026 | marketbeat.comSupernus Pharmaceuticals to Participate in the Bank of America 2026 Health Care ConferenceMay 6, 2026 | globenewswire.comDoes Q1 2026 Earnings Beat Reshape the Bull Case for Supernus Pharmaceuticals (SUPN)?May 6, 2026 | finance.yahoo.comSUPN Q1 deep dive: Growth products drive revenue upside, guidance highlights execution challengesMay 6, 2026 | msn.comSupernus Pharmaceuticals’s (NASDAQ:SUPN) Q1 CY2026 Sales Beat EstimatesMay 6, 2026 | finance.yahoo.comSupernus Pharmaceuticals Q1 Earnings Call HighlightsMay 5, 2026 | marketbeat.comSupernus Pharmaceuticals, Inc. (SUPN) Q1 2026 Earnings Call TranscriptMay 5, 2026 | seekingalpha.comSupernus Pharmaceuticals Earnings Call Signals Growth MomentumMay 5, 2026 | tipranks.comSupernus (SUPN) Q1 Earnings: Taking a Look at Key Metrics Versus EstimatesMay 5, 2026 | zacks.comSupernus Pharmaceuticals (SUPN) Beats Q1 Earnings and Revenue EstimatesMay 5, 2026 | zacks.comSupernus Pharmaceuticals (SUPN) Stock Rises on Q1 2026 EarningsMay 5, 2026 | quiverquant.comQSupernus Pharmaceuticals (NASDAQ:SUPN) Issues Quarterly Earnings ResultsMay 5, 2026 | marketbeat.comSupernus Announces First Quarter 2026 Financial ResultsMay 5, 2026 | globenewswire.comSupernus Pharmaceuticals Q1 2026 earnings previewMay 5, 2026 | msn.comSupernus Pharmaceuticals, Inc. $SUPN Shares Sold by Pictet Asset Management Holding SAMay 1, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAPNHY, BBIO, RDY, and SUPN Company DescriptionsAspen Pharmacare OTCMKTS:APNHY$8.14 0.00 (0.00%) As of 05/22/2026Aspen Pharmacare Holdings Limited, together with its subsidiaries, manufactures and supplies specialty and branded pharmaceutical products worldwide. It operates in Commercial Pharmaceuticals and Manufacturing segments. The company provides general anesthetics, muscle relaxants, and topical agents under the Anaesthetics brand; and a range of injectable anticoagulants with a focus on low molecular weight heparins, Xa inhibitors, and heparin derivatives under the Thrombosis brand. It also offers branded consumer, prescription, and over-the-counter products under the regional brands, such as Circadin, Foxair, Maltofer, Mybulen, and Zyloric for various types of anesthetic comprises sleeping aid, respiratory, iron supplement, analgesic, and uric acid production inhibitor. In addition, the company manufactures and sells active pharmaceutical ingredients and finished dose form products to third-party customers. Aspen Pharmacare Holdings Limited was founded in 1850 and is headquartered in Durban, South Africa.BridgeBio Pharma NASDAQ:BBIO$69.12 -1.16 (-1.65%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$67.88 -1.24 (-1.80%) As of 05/22/2026 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.Dr. Reddy's Laboratories NYSE:RDY$13.60 +0.05 (+0.34%) Closing price 05/22/2026 03:59 PM EasternExtended Trading$13.62 +0.02 (+0.17%) As of 05/22/2026 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The company offers its products for various therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.Supernus Pharmaceuticals NASDAQ:SUPN$48.21 -1.17 (-2.37%) As of 05/22/2026 04:00 PM EasternSupernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age. It also offers comprise Qelbree, a novel non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, the company's product candidates include SPN-830, a late-stage drug/device combination product candidate for the treatment of off episodes in PD patients; SPN-817, a novel first-in-class selective acetylcholinesterase inhibitor, which is in Phase II clinical trials for the treatment of epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; SPN-443, a preclinical product for the treatment of ADHD/CNS; and SPN-446 for narcolepsy and SPN-448 for the treatment of CNS which is in discovery stage. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Rockville, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/18 - 05/22 Was Decker’s Double Beat a Bullish Signal—Or Mere HOKA’s-Pocus? Workday Validates AI Flywheel: Stock Price Recovery Begins SpaceX IPO: Opportunity? Or the Ultimate Hype Trade? Overextended, e.l.f. Beauty Is Primed to Rebound in Back Half Deere Beats Q2 Estimates, But Ag Weakness Weighs on Outlook NVIDIA Price Pullback? Don’t Count on It, Business Is Accelerating Palantir and Dell Build an AI OS for the Paranoid Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
